Accelerate Therapeutic Efficacy & Delivery Potential of Exosome & EVs
Welcome to the 7th Exosome-Based Therapeutics Development Summit
Boosting Exosome & Extra-Cellular Vesicle Therapies & Delivery Carriers with Optimal Characterization, Improved Tropism & GMP-Grade Production For Regenerative & Precision Medicine
The exosome and extracellular vesicle (EV) fields moved closer to groundbreaking clinical and commercial breakthroughs in 2025, with major therapeutic advancements showcased by leading biopharma companies including Rion, Direct Biologics, Aegle Therapeutics, Aruna Bio, EXO Biologics, and more.
Highlighting the industry's progress throughout the year, the 7th Exosome-Based Therapeutics Development Summit returned to Boston with never-before-seen data, covering the full pipeline from discovery to optimized characterization, scalable manufacturing, and clinical outcomes. As the only industry-dedicated summit focused on bridging science and business, it played a pivotal role in advancing effective regenerative and precision medicines.
More than 80 key experts across exosome biology, Exosome Biology, R&D, CMC to Business Development came together for an unparalleled opportunity to exchange insights, foster partnerships, and map out the therapeutic efficacy and delivery potential of exosomes and EVs on the path to commercialization and patient impact.
"As an emerging therapeutic modality, it is essential that leaders in the exosome and EV space come together to exchange knowledge in an effort to accelerate translation of this technology into clinical practice"
Chris Paradise, Vice President – Research & Development
2025 Official Brochure Available Now
2025 World-Class Speaker Faculty Includes:
Speaker Announcement
Presentied On...
Biological Standardization & Development of Reference Reagents & Bioactivity Assays for Extracellular Vesicles
News Hub
Hear From Our 2025 Speakers
“I look forward to engaging with industry experts to drive innovation, regulatory alignment, and translational success in exosome therapeutics”
Sandra Mores, Chief Operating Officer
EXO Biologics
“This meeting is a chance to exchange ideas at the leading edge of exosome science. I value the opportunity to share insights from the lab, learn from others, challenge my assumptions and spark collaborations to drive real breakthroughs”
Mickey Pentecost, Chief Scientific Officer
Diadem Biotherapeutics
2025 Sponsors
Explore Related Events
